CAMZYOS is Now Included in the 2024 AHA/ACC/Multisociety HCM Guideline
CAMZYOS® is the first and only approved cardiac myosin inhibitor that targets HCM at the source.1,2
CAMZYOS is an allosteric and reversible inhibitor selective for cardiac myosin that helps to modulate the number of myosin heads in the off state.
This reduces the number of
Access to everything you need to start
appropriate patients on CAMZYOS.
Locate REMS-certified healthcare providers with CAMZYOS treatment experience
Find information about patient support, program details,
enrollment information, and downloadable resources.
HCM=hypertrophic cardiomyopathy; NYHA=New York Heart Association; REMS=Risk Evaluation and Mitigation Strategy.
This website is best viewed
using the horizontal display
on your tablet device.
This website is best viewed
using the vertical display
on your mobile device.
References: